• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Bempedoic Acid Reduces CV Risk in Latinx Population with Statin-Intolerance: Daily Dose

Bempedoic Acid Reduces CV Risk in Statin-Intolerant Individuals: Daily Dose / Image Credit: ©New Africa/AdobeStock
©New Africa/AdobeStock

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

Last week, we reported on findings from a study presented at the American College of Cardiology’s 73rd Annual Scientific Session, held April 6-8, 2024, in Atlanta, Georgia.

The study

Researchers conducted an exploratory analysis of the CLEAR Outcomes clinical trial. The CLEAR Outcomes study, which enrolled nearly 14 000 participants at high CV risk with statin intolerance, presented the opportunity to explore the effects of bempedoic acid on CV risk reduction among the study’s subpopulation of Hispanic/Latinx participants.

The participants in CLEAR Outcomes were randomly assigned to receive bempedoic acid 180 mg or placebo. The primary endpoint was a 4-component composite of major adverse CV events (MACE-4), defined as death from CV causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization.

The findings

Hispanic/Latinx individuals recruited from Latin America and North America comprised 17% of the cohort, with 1190 receiving bempedoic acid and 1143 receiving placebo.

Researchers noted that at month 6, least-squares mean placebo-corrected LDL-C change from baseline (-21.0% [95% CI -23.0 to -19.0] and -21.2% [95% CI -22.1 to -20.2]) and placebo-corrected absolute LDL-C change from baseline (-27.2 mg/dL [95% CI -29.8 to -24.5] and -29.7 [95% CI -30.9 to -28.4]) were similar in Hispanic/Latinx participants and non-Hispanic/Latinx individuals, respectively.

Investigators also found that bempedoic acid reduced the risk of MACE-4 compared to placebo in both non-Hispanic/Latinx and Hispanic/Latinx participants. Among Hispanic/Latinx individuals in the bempedoic acid group, there were 85 MACE-4 events vs 106 events among those who received placebo (HR 0.77, 95% CI 0.58-1.02). There were 734 events observed among non-Hispanic/Latinx participants in the bempedoic acid group compared to 821 events among non-Hispanic/Latinx individuals in the placebo group (HR 0.89, 95% CI 0.80-0.98).

Authors' comment

"Ongoing attention is needed for clinical trial representation, clinical patterns of CV disease, and optimizing CV risk management among the growing Hispanic/Latinx population."

Click here for more details.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2024 MJH Life Sciences

All rights reserved.